^
    Evidence Level:
    Sensitive: A1 - Approval

    [IDH2 mutation-Acute Myelogenous Leukemia-enasidenib]

    Source:
    FDA
    Test:

    Abbott RealTime IDH2

    Excerpt:
    IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDAapproved test